

RNA Therapy Clinical Trials Market Size, Trends, Analysis, and Outlook By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/RF5D050A0B4CEN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: RF5D050A0B4CEN

Abstracts

The global RNA Therapy Clinical Trials market size is poised to register 6.14% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global RNA Therapy Clinical Trials market across By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others).

The RNA Therapy Clinical Trials market is experiencing rapid growth, propelled by the growing interest in RNA-based therapeutics, advancements in nucleic acid delivery technologies, and the need for innovative treatment options for various diseases. RNA therapies, including mRNA, siRNA, and antisense oligonucleotides, hold immense potential for targeting specific disease pathways, modulating gene expression, and addressing unmet medical needs. With a surge in RNA-focused research and investment, the market for RNA therapy clinical trials is poised for significant expansion,

paving the way for novel therapeutic breakthroughs across a wide range of indications.

RNA Therapy Clinical Trials Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The RNA Therapy Clinical Trials market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of RNA Therapy Clinical Trials survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the RNA Therapy Clinical Trials industry.

Key market trends defining the global RNA Therapy Clinical Trials demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

RNA Therapy Clinical Trials Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The RNA Therapy Clinical Trials industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support RNA Therapy Clinical Trials companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the RNA Therapy Clinical Trials industry

Leading RNA Therapy Clinical Trials companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report

provides key strategies opted for by the top 10 RNA Therapy Clinical Trials companies.

RNA Therapy Clinical Trials Market Study- Strategic Analysis Review

The RNA Therapy Clinical Trials market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

RNA Therapy Clinical Trials Market Size Outlook- Historic and Forecast Revenue in Three Cases

The RNA Therapy Clinical Trials industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

RNA Therapy Clinical Trials Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America RNA Therapy Clinical Trials Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various RNA Therapy Clinical Trials market segments. Similarly, Strong end-user demand is encouraging Canadian RNA Therapy Clinical Trials companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico RNA Therapy Clinical Trials market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe RNA Therapy Clinical Trials Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European RNA Therapy Clinical Trials industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European RNA Therapy Clinical Trials market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific RNA Therapy Clinical Trials Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for RNA Therapy Clinical Trials in Asia Pacific. In particular, China, India, and South East Asian RNA Therapy Clinical Trials markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America RNA Therapy Clinical Trials Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa RNA Therapy Clinical Trials Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East RNA Therapy Clinical Trials market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for RNA Therapy Clinical Trials.

RNA Therapy Clinical Trials Market Company Profiles

The global RNA Therapy Clinical Trials market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Charles River Laboratories International Inc, ICON Plc, IQVIA, Laboratory Corp of America Holdings, Medpace Holdings Inc, Novotech, PAREXEL International Corp, PPD Inc, Syneos Health, Veristat Llc

Recent RNA Therapy Clinical Trials Market Developments

The global RNA Therapy Clinical Trials market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

RNA Therapy Clinical Trials Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Modality

RNA interference

Antisense therapy

Messenger RNA

Oligonucleotide, non-antisense, non-RNAi

By Phase

Phase I

Phase II

Phase III

Phase IV

By Therapeutic Areas

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Charles River Laboratories International Inc

ICON Plc

IQVIA

Laboratory Corp of America Holdings

Medpace Holdings Inc

Novotech

PAREXEL International Corp

PPD Inc

Syneos Health

Veristat Llc

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 RNA Therapy Clinical Trials Market Overview and Key Findings, 2024
- 1.2 RNA Therapy Clinical Trials Market Size and Growth Outlook, 2021- 2030
- 1.3 RNA Therapy Clinical Trials Market Growth Opportunities to 2030
- 1.4 Key RNA Therapy Clinical Trials Market Trends and Challenges
 - 1.4.1 RNA Therapy Clinical Trials Market Drivers and Trends
 - 1.4.2 RNA Therapy Clinical Trials Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading RNA Therapy Clinical Trials Companies

2. RNA THERAPY CLINICAL TRIALS MARKET SIZE OUTLOOK TO 2030

- 2.1 RNA Therapy Clinical Trials Market Size Outlook, USD Million, 2021- 2030
- 2.2 RNA Therapy Clinical Trials Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. RNA THERAPY CLINICAL TRIALS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. RNA THERAPY CLINICAL TRIALS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
 - By Modality
 - RNA interference
 - Antisense therapy

Messenger RNA

Oligonucleotide, non-antisense, non-RNAi

By Phase

Phase I

Phase II

Phase III

Phase IV

By Therapeutic Areas

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific RNA Therapy Clinical Trials Market, 2025

5.2 Asia Pacific RNA Therapy Clinical Trials Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific RNA Therapy Clinical Trials Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe RNA Therapy Clinical Trials Market, 2025

5.5 Europe RNA Therapy Clinical Trials Market Size Outlook by Type, 2021- 2030

5.6 Europe RNA Therapy Clinical Trials Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America RNA Therapy Clinical Trials Market, 2025

5.8 North America RNA Therapy Clinical Trials Market Size Outlook by Type, 2021- 2030

5.9 North America RNA Therapy Clinical Trials Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America RNA Therapy Clinical Trials Market, 2025

5.11 South America Pacific RNA Therapy Clinical Trials Market Size Outlook by Type, 2021- 2030

5.12 South America RNA Therapy Clinical Trials Market Size Outlook by Application, 2021- 2030

- 5.13 Key Findings for Middle East and Africa RNA Therapy Clinical Trials Market, 2025
- 5.14 Middle East Africa RNA Therapy Clinical Trials Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa RNA Therapy Clinical Trials Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US RNA Therapy Clinical Trials Market Size Outlook and Revenue Growth Forecasts
- 6.2 US RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia RNA Therapy Clinical Trials Industry Drivers and Opportunities

- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East RNA Therapy Clinical Trials Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa RNA Therapy Clinical Trials Industry Drivers and Opportunities

7. RNA THERAPY CLINICAL TRIALS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. RNA THERAPY CLINICAL TRIALS COMPANY PROFILES

- 8.1 Profiles of Leading RNA Therapy Clinical Trials Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics
- Charles River Laboratories International Inc
- ICON Plc
- IQVIA
- Laboratory Corp of America Holdings
- Medpace Holdings Inc
- Novotech
- PAREXEL International Corp
- PPD Inc
- Syneos Health
- Veristat Llc

9. APPENDIX

- 9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

I would like to order

Product name: RNA Therapy Clinical Trials Market Size, Trends, Analysis, and Outlook By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi), By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/RF5D050A0B4CEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF5D050A0B4CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970